Humanigen Implements Strategic Realignment of Pipeline and R

Short Hills, New Jersey--(Newsfile Corp. - July 26, 2022) - Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab, a first-in class

Related Keywords

United Kingdom , Australia , United States , New Zealand , Australian , American , Cameron Durrant , Tim Morris , Jersey Newsfile Corp , Leukemia Research , International Working Group Criteria , Nasdaq , Leukaemia Foundation , Research Institute , Humanigen Inc , Australian Health , American Journal Of Blood Research , American Cancer Society , Therapeutic Goods Administration , Short Hills , International Working Group , Principal Investigator , Project Orbis , Australian Registry , South Australian Health , Medical Research Institute , Retrieved July , Blood Research , England Journal , Humanigen , Implements , Strategic , Realignment , Pipeline , Resources , Chieve , Linical , Ilestones ,